Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension
Mohamed Ahmed1,2,3, Edmund Miller2,3,4
1Neonatal-Perinatal Medicine, Pediatrics Department Cohen Children's Hospital at New York, Northwell Health System.
Abstract:
Macrophage migration inhibitory factor (MIF) has been described as a pro-inflammatory cytokine and regulator of neuro-endocrine function. It plays an important upstream role in the inflammatory cascade by promoting the release of other inflammatory cytokines such as TNF-alpha and IL-6, ultimately triggering a chronic inflammatory immune response. As lungs can synthesize and release MIF, many studies have investigated the potential role of MIF as a biomarker in assessment of patients with pulmonary arterial hypertension (PAH) and using anti-MIFs as a new therapeutic modality for PAH.
Insights
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine implicated in chronic inflammation. Research explores MIF as a biomarker and therapeutic target for pulmonary arterial hypertension (PAH).
Area of Science:
- Immunology
- Pulmonology
- Endocrinology
Background:
- Macrophage migration inhibitory factor (MIF) is recognized as a pro-inflammatory cytokine.
- MIF regulates neuro-endocrine functions and initiates inflammatory cascades by promoting cytokines like TNF-alpha and IL-6.
- This leads to chronic inflammatory immune responses.
Purpose of the Study:
- Investigate the role of MIF as a biomarker in pulmonary arterial hypertension (PAH).
- Explore the potential of anti-MIF therapies for treating PAH.
Main Methods:
- Studies investigated the synthesis and release of MIF in the lungs.
- Research focused on assessing MIF's correlation with PAH.
- Exploration of anti-MIF agents as therapeutic strategies.
Main Results:
- MIF's involvement in the inflammatory pathway relevant to PAH is highlighted.
- Potential utility of MIF as a diagnostic or prognostic marker in PAH is suggested.
- Anti-MIF therapies are being considered for PAH treatment.
Conclusions:
- MIF plays a significant role in the inflammatory processes underlying PAH.
- MIF presents potential as a biomarker for PAH assessment.
- Targeting MIF with anti-MIF therapies offers a promising therapeutic avenue for PAH.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...